[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334394-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334394-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","discovery-of-md-265-a-potent-mdm2-degrader-that-achieves-complete-tumor-regression-and-improves-long-term-survival-of-mice-with-leukemia","Discovery of MD-265 - A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia","","MDM2 represents an attractive therapeutic target in human cancers. This study reports the discovery of MD-265, a PROTAC-based MDM2 degrader, and evaluates its antitumor potential and mechanism through extensive in vitro and in vivo experiments. MD-265 depletes MDM2 in cancer cells at concentrations as low as 1 nM, activates p53 in wild-type p53 backgrounds, selectively suppresses wild-type p53 leukemia cells, and shows no activity in mutated p53 models. In leukemia mouse studies, it enables persistent tumor regression, improves survival under weekly dosing, and exhibits strong intravenous PK in mice, rats, and dogs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/discovery-of-md-265-a-potent-mdm2-degrader-that-achieves-complete-tumor-regression-and-improves-long-term-survival-of-mice-with-leukemia/334394/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/discovery-of-md-265-a-potent-mdm2-degrader-that-achieves-complete-tumor-regression-and-improves-long-term-survival-of-mice-with-leukemia/334394.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is MD-265 and what therapeutic mechanism does it target?","Question",{"text":63,"@type":64},"MD-265 is a PROTAC MDM2 degrader designed to degrade MDM2 and thereby activate p53 signaling. By reducing MDM2 protein levels, it enables strong p53 activation in wild-type p53 cancer cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does MD-265 affect p53 status in different leukemia cell lines?",{"text":68,"@type":64},"MD-265 strongly activates p53 and inhibits growth in leukemia cell lines carrying wild-type p53. It shows no activity in cell lines with mutated p53.",{"name":70,"@type":61,"acceptedAnswer":71},"What in vivo outcomes were observed with MD-265 in leukemia mouse models?",{"text":72,"@type":64},"MD-265 produced complete and persistent tumor regression in a leukemia xenograft model and significantly improved survival in a disseminated leukemia model, including under weekly administration, without signs of toxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334394,1790466761,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/jmc](pubs.acs.org/jmc)  Article   \nDiscovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia  \nAngelo Aguilar,\\# Jiuling Yang,\\# Yangbing Li,\\# Donna McEachern, Liyue Huang, Stevenchoukry Razzouk, and Shaomeng Wang*  \n Cite This: J. Med. Chem. 2024, 67, 19503−19518  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: MDM2 has been pursued as an attractive therapeutic target for human cancers. Herein, we describe our discovery of MD-265 as a promising PROTAC MDM2 degrader and extensive in vitro and in vivo evaluations of its therapeutic potential and mechanism of action. MD-265 effectively depleted MDM2 protein in cancer cells at concentrations as low as 1 nM, leading to strong activation of p53 in cancer cells carrying wild-type p53. It selectively inhibited the growth of wild-type p53 leukemia cell lines and showed no activity in mutated p53 lines. MD-265 achieved persistent tumor regression in a leukemia xenograft model without causing any signs of toxicity and dramatically improved survival of mice in a disseminated leukemia model even with a weekly administration. MD-265 displayed an excellent intravenous PK profile in mice, rats, and dogs. MD-265 is a promising MDM2 degrader for advanced preclinical development for the treatment of human cancers.  \n■ INTRODUCTION  \nThe tumor suppressor p53 is a transcriptional factor and has been considered as the guardian of the human genome. Because of its powerful tumor suppressor function, p53 mutations are found in approximately 50% of human cancers, which lead to the loss of its tumor suppressor function or even a gain of oncogenic activity.1 In the other half of human cancers, p53 retains its wild-type status, but its tumor suppressor function is effectively inhibited by the murine double minute 2 (MDM2) protein through their direct protein−protein interaction (PPI).2−7 Therefore, targeting the MDM2−p53 PPI has been pursued as a novel cancer therapeutic strategy, which has resulted in the advancement of several potent and selective small molecule MDM2 inhibitors into clinical development for cancer treatment.8−21 However, since p53 is a transcription factor and MDM2 is a direct target of p53, blocking the MDM2−p53 PPI by MDM2 inhibitors results in p53 activation, leading to upregulation of MDM2 in both mRNA and protein levels.5 Increased levels of MDM2 protein by MDM2 inhibitors attenuate the activation of p53, limiting the potential clinical efficacy of MDM2 inhibitors. In addition, due to the oncogenic activity of MDM2 protein, increased levels of MDM2 protein by MDM2 inhibitors may cause unwanted side effects. Although a number of MDM2 inhibitors have been advanced into Phase 2/3 clinical development, no MDM2 inhibitor has been approved for the treatment of human cancers to date. Hence, a new therapeutic strategy to target MDM2 is highly desirable.  \nIn recent years, induced targeted protein degradation (TPD) using the proteolysis-targeting chimera (PROTAC) technology has become a powerful approach for the discovery and development of novel therapeutics for the treatment of human cancers and other human diseases.22−25 In our previous study, we have reported the design and evaluation of first-in-class MDM2 degraders using the PROTAC technology, exemplified by MD-224.26 Herein, we describe further optimization of MD-224, which resulted in the discovery of MD-265 as a novel and very promising PROTAC MDM2 degrader. Our data demonstrate that MD-265 was highly potent and effective in inducing degradation of MDM2 protein, leading to strong p53 activation in cancer cells carrying wild-type p53. MD-265 potently inhibited cell growth in human acute leukemia cancer cell lines carrying wild-type p53 and demonstrated no activity","cbCaiuOyNYMBAn9b","https://ap.wps.com/l/cbCaiuOyNYMBAn9b","pdf",3681775,16,"English","# Abstract\n# Introduction\n# Results and Discussion","[{\"question\":\"What is MD-265 and what therapeutic mechanism does it target?\",\"answer\":\"MD-265 is a PROTAC MDM2 degrader designed to degrade MDM2 and thereby activate p53 signaling. By reducing MDM2 protein levels, it enables strong p53 activation in wild-type p53 cancer cells.\"},{\"question\":\"How does MD-265 affect p53 status in different leukemia cell lines?\",\"answer\":\"MD-265 strongly activates p53 and inhibits growth in leukemia cell lines carrying wild-type p53. It shows no activity in cell lines with mutated p53.\"},{\"question\":\"What in vivo outcomes were observed with MD-265 in leukemia mouse models?\",\"answer\":\"MD-265 produced complete and persistent tumor regression in a leukemia xenograft model and significantly improved survival in a disseminated leukemia model, including under weekly administration, without signs of toxicity.\"}]","Discovery of MD-265 - A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia | PDF",1790006495]